BENITIONSClinical Trial Intelligence

Exclusion of Intra-atrial Thrombus Before Catheter Ablation

不适用 已完成 NCT03455673

适应症Atrial Fibrillation, Thrombi
分期不适用
申办方Groupe Hospitalier de la Rochelle Ré Aunis
状态已完成
受试者人数3,160 人
干预(药物)ATE score
开始日期2018年9月18日
完成日期2020年11月7日
结果公布日2023年12月22日

摘要

Atrial fibrillation is the most frequent heart rhythm disorder. Its symptomatic forms, resistant to drug therapy, require invasive management (catheter ablation), which exposes to potentially serious complications including thromboembolic complications. Despite anticoagulant treatment, intra-atrial thrombus, which is a contraindication to catheter ablation, is detected in nearly 2 % of cases. Its diagnosis requires prior transoesophageal echocardiography, an unpleasant examination. A previous study (NCT02199080) showed that a zero ATE score, defined by no heart failure, no hypertension, no history of stroke, d-dimer \< 270 ng/mL, has a negative predictive value of 100 % for the exclusion of intra-atrial thrombus. The objective of the study is to confirm the negative predictive value, sensitivity and specificity of the ATE score for the exclusion of intra-atrial thrombus.

Number of Patients With Atrial Thrombus and a Zero ATE Score

at most 48 hours before ablation · Participants

Atrial Fibrillation2 Participants
Atrial Fibrillation816 Participants
Atrial Fibrillation27 Participants
Atrial Fibrillation2227 Participants

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

全部试验

本页整理自 ClinicalTrials.gov 的公开数据,不构成医疗建议,也不构成投资建议。请务必咨询专业医师。